// App-Quantinova.ai

: Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Researchers

Presenter

  • Ruben A. Mesa

Principal Investigators

  • Francisco Cervantes

  • Claire N. Harrison

  • Adam J. Mead

  • Alessandro M. Vannucchi

  • Srdan Verstovsek

  • Lixia Wang

  • Tanya Granston

  • John Mascarenhas

Medical Centers

  • UT Health San Antonio MD Anderson, San Antonio, TX

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Department of Medical Oncology, Guys and St Thomas NHS Foundation Trust, London, United Kingdom

  • NIHR Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom

  • CRIMM, AOU Careggi, University of Florence, Florence, Italy

  • 1.MD Anderson Cancer Center, Houston, TX

  • CTI BioPharma Corporation, Seattle, WA

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Locations

  • United States

  • Spain

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Thrombocytopenia

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

  • Pacritinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved